Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies-Reference-Cited by-同舟云学术

Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies

Published:2002-10 Issue:2 Volume:54 Page:357-364
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Firat Selim,Byhardt Roger W,Gore Elizabeth

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference33 articles.

1. Cancer statistics 2000;Greenlee;CA Cancer J Clin,2000

2. Radiation Therapy Oncology Group 88-08, and Eastern Cooperative Oncology Group 4588;Sause;J Natl Cancer Inst,1995

3. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer;Dillman;N Engl J Med,1990

4. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer;Komaki;Int J Radiat Oncol Biol Phys,2000

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study;Clinical Lung Cancer;2024-07

2. Diagnosis of Metastatic Non-Small Cell Lung Cancer during Hospitalization: Missed Opportunity for Optimal Supportive Care?;Cancers;2024-03-20

3. Establishing and Validating a novel Prognostic Model in the Initial Diagnosis of Non-small Cell Lung Cancer with Bone Metastases;Journal of Cancer;2024

4. Palliative radiotherapy in the older adult;Palliative Radiation Oncology;2024

5. Populations particulières : patients de performance status 2 ou plus;Revue des Maladies Respiratoires Actualités;2023-10